NASDAQ:CHRS

Coherus BioSciences Stock Forecast, Price & News

$13.26
-0.13 (-0.97 %)
(As of 07/29/2021 03:05 PM ET)
Add
Compare
Today's Range
$13.20
$13.48
50-Day Range
$12.68
$15.41
52-Week Range
$12.56
$22.22
Volume5,102 shs
Average Volume1.04 million shs
Market Capitalization$1.00 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.08
30 days | 90 days | 365 days | Advanced Chart
Receive CHRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.


Coherus BioSciences logo

About Coherus BioSciences

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.51 out of 5 stars

Medical Sector

941st out of 2,214 stocks

Biological Products, Except Diagnostic Industry

141st out of 213 stocks

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Coherus BioSciences (NASDAQ:CHRS) Frequently Asked Questions

Is Coherus BioSciences a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Coherus BioSciences stock.
View analyst ratings for Coherus BioSciences
or view top-rated stocks.

What stocks does MarketBeat like better than Coherus BioSciences?

Wall Street analysts have given Coherus BioSciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Coherus BioSciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Coherus BioSciences' next earnings date?

Coherus BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Coherus BioSciences
.

How can I listen to Coherus BioSciences' earnings call?

Coherus BioSciences will be holding an earnings conference call on Thursday, August 5th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) posted its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($2.37) EPS for the quarter, missing the consensus estimate of $0.09 by $2.46. The biotechnology company had revenue of $83.03 million for the quarter, compared to the consensus estimate of $97.87 million. Coherus BioSciences had a negative net margin of 17.23% and a negative trailing twelve-month return on equity of 34.76%.
View Coherus BioSciences' earnings history
.

How has Coherus BioSciences' stock price been impacted by COVID-19?

Coherus BioSciences' stock was trading at $15.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CHRS stock has decreased by 16.1% and is now trading at $13.31.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CHRS?

4 Wall Street analysts have issued 1-year price objectives for Coherus BioSciences' stock. Their forecasts range from $22.00 to $36.00. On average, they anticipate Coherus BioSciences' share price to reach $27.80 in the next twelve months. This suggests a possible upside of 108.9% from the stock's current price.
View analysts' price targets for Coherus BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Coherus BioSciences' key executives?

Coherus BioSciences' management team includes the following people:
  • Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 66, Pay $1.82M)
  • Mr. Vincent R. Anicetti, Chief Operating Officer (Age 66, Pay $795.39k)
  • Mr. Vladimir Vexler, Chief Scientific Officer (Age 63, Pay $768.47k)
  • Dr. V. Bryan Lawlis Jr., Science Director & Member of Scientific Advisory Board (Age 69, Pay $87.5k)
  • Mr. McDavid Stilwell, Chief Financial Officer (Age 50)
  • Mr. Thomas F. Fitzpatrick, Chief Legal Officer
  • Mr. Chris Thompson, Exec. VP of Sales
  • Ms. Rebecca Sunshine, Exec. VP of HR (Age 58)
  • Dr. Barbara K. Finck, Chief Clinical Advisor, Acting Chief Medical Officer & Member of Scientific Advisory Board (Age 74)
  • Mr. Michael A. Fleming, Exec. VP of Corp. & Competitive Strategy

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences CEO Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among Coherus BioSciences' employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Coherus BioSciences' key competitors?

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.83%) and State of Alaska Department of Revenue (0.06%). Company insiders that own Coherus BioSciences stock include Dennis M Lanfear, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends for Coherus BioSciences
.

Which major investors are buying Coherus BioSciences stock?

CHRS stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., and State of Alaska Department of Revenue.
View insider buying and selling activity for Coherus BioSciences
or or view top insider-buying stocks.

How do I buy shares of Coherus BioSciences?

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coherus BioSciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $13.31.

How much money does Coherus BioSciences make?

Coherus BioSciences has a market capitalization of $1.01 billion and generates $475.82 million in revenue each year. The biotechnology company earns $132.24 million in net income (profit) each year or $1.62 on an earnings per share basis.

How many employees does Coherus BioSciences have?

Coherus BioSciences employs 310 workers across the globe.

What is Coherus BioSciences' official website?

The official website for Coherus BioSciences is www.coherus.com.

Where are Coherus BioSciences' headquarters?

Coherus BioSciences is headquartered at 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065.

How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]


This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.